Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

non-small cell lung cancer, egfr activating mutation, cell cycle deregulation, egfr-tki resistant mutation, nsclc, egfr activating mutations, third-generation egfr-tki, cell cycle signaling pathway aberrations, cdk4/6 inhibitors, interventional, phase2